CD70 and neoplasm: This combination exhibited the highest efficacy, leading to an extension of survival in mice with tumor burden for up to 60 days.445 Another study by Lanqi Gong et al. demonstrated that CD70 blockade, when combined with anti-PD-1 treatment, synergistically reinvigorated T-cell immunity against nasopharyngeal carcinoma.